{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:02:34Z","timestamp":1787166154562,"version":"build-2736575974"},"reference-count":30,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Classical Hodgkin lymphoma (HL) patients presenting a relapsed\/refractory (R\/R) disease are currently managed with salvage chemotherapy followed by autologous stem cell transplantation (ASCT). However, almost 25\u201330% of these patients fail to achieve a complete response (CR) with standard salvage regimens. In this retrospective study, we evaluated the efficacy of a combination of brentuximab vedotin (BV) and pembrolizumab in a series of HL patients presenting with a high-risk, multi-refractory disease. Patients achieving a Deauville score \u22644 proceeded to ASCT consolidation. After ASCT, patients received BV as maintenance for a total of 16 administrations. We collected data from 10 patients with a median age of 30.7 years. At a median follow-up of 16.5 months, we reported a complete metabolic remission (CMR) in eight patients (80%), with seven patients (70%) directly proceeding to ASCT (the other two patients in CMR are still undergoing treatment). BV consolidation was started in six patients and completed by three patients (one ongoing, two interruption). Two patients (20%) presented a progressive disease (PD) and subsequently died, while the others are still in CMR. The BV and pembrolizumab combination is a very effective bridge treatment to ASCT for high-risk R\/R HL patients.<\/jats:p>","DOI":"10.3390\/cancers14040982","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T22:43:22Z","timestamp":1644965002000},"page":"982","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed\/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis"],"prefix":"10.3390","volume":"14","author":[{"given":"Fulvio","family":"Massaro","sequence":"first","affiliation":[{"name":"Department of Haematology, Institut Jules Bordet (ULB), 1070 Brussels, Belgium"},{"name":"PhD Program in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, 41121 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Meuleman","sequence":"additional","affiliation":[{"name":"Department of Haematology, Institut Jules Bordet (ULB), 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Bron","sequence":"additional","affiliation":[{"name":"Department of Haematology, Institut Jules Bordet (ULB), 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7079-8722","authenticated-orcid":false,"given":"Marie","family":"Vercruyssen","sequence":"additional","affiliation":[{"name":"Department of Haematology, Institut Jules Bordet (ULB), 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Maerevoet","sequence":"additional","affiliation":[{"name":"Department of Haematology, Institut Jules Bordet (ULB), 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC\/LYSA\/FIL H10 Trial","volume":"35","author":"Girinsky","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood-2015-11-679407","article-title":"PET-CT for Staging and Early Response: Results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma Study","volume":"127","author":"Barrington","year":"2016","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose\u2013Positron Emission Tomography Imaging: Southwest Oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose Intensification with Autologous Bone-Marrow Transplantation in Relapsed and Resistant Hodgkin\u2019s Disease: Results of a BNLI Randomised Trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive Conventional Chemotherapy Compared with High-Dose Chemotherapy with Autologous Haemopoietic Stem-Cell Transplantation for Relapsed Chemosensitive Hodgkin\u2019s Disease: A Randomised Trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2017-06-788877","article-title":"Prognostic Significance of Baseline Metabolic Tumor Volume in Relapsed and Refractory Hodgkin Lymphoma","volume":"130","author":"Moskowitz","year":"2017","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hon.2589","article-title":"Treating Hodgkin Lymphoma in the New Millennium: Relapsed and Refractory Disease","volume":"37","author":"LaCasce","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin\u2019s Lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"JCO"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in Relapsed or Refractory Hodgkin Lymphoma: 2-Year Follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim Results of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification Lymphoma Response Criteria in the Era of Immunomodulatory Therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab Vedotin in Combination with Nivolumab in Relapsed or Refractory Hodgkin Lymphoma: 3-Year Study Results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1002\/cam4.3262","article-title":"Effectiveness of Chemotherapy after Anti-PD-1 Blockade Failure for Relapsed and Refractory Hodgkin Lymphoma","volume":"9","author":"Casadei","year":"2020","journal-title":"Cancer Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/hon.2803","article-title":"Potential Survival Benefit for Patients Receiving Autologous Hematopoietic Stem Cell Transplantation after Checkpoint Inhibitors for Relapsed\/Refractory Hodgkin Lymphoma: A Real-Life Experience","volume":"38","author":"Casadei","year":"2020","journal-title":"Hematol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/ajh.25154","article-title":"Efficacy of Chemotherapy or Chemo-Anti-PD-1 Combination after Failed Anti-PD-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Series from Lysa Centers","volume":"93","author":"Rossi","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1634\/theoncologist.2020-0167","article-title":"Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy","volume":"25","author":"Carreau","year":"2020","journal-title":"Oncologist"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/bloodadvances.2020003556","article-title":"Autologous Stem Cell Transplantation after Anti-PD-1 Therapy for Multiply Relapsed or Refractory Hodgkin Lymphoma","volume":"5","author":"Merryman","year":"2021","journal-title":"Blood Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","article-title":"International Working Group Consensus Response Evaluation Criteria in Lymphoma (RECIL 2017)","volume":"28","author":"Younes","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Moskowitz, A.J., Shah, G., Sch\u00f6der, H., Ganesan, N., Drill, E., Hancock, H., Davey, T., Perez, L., Ryu, S., and Sohail, S. (2021). Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. J. Clin. Oncol.","DOI":"10.1200\/JCO.21.01056"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/annonc\/mdt349","article-title":"Immunological Off-Target Effects of Standard Treatments in Gastrointestinal Cancers","volume":"25","author":"Duffy","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3626","article-title":"The Secret Ally: Immunostimulation by Anticancer Drugs","volume":"11","author":"Galluzzi","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/hematology.2021000311","article-title":"How to Choose First Salvage Therapy in Hodgkin Lymphoma: Traditional Chemotherapy vs Novel Agents","volume":"2021","author":"Driessen","year":"2021","journal-title":"Hematology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1182\/blood.V126.23.3982.3982","article-title":"Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma","volume":"126","author":"LaCasce","year":"2015","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41408-019-0265-x","article-title":"First Salvage Treatment with Bendamustine and Brentuximab Vedotin in Hodgkin Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi","volume":"9","author":"Broccoli","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Cancer Leukemia Group B Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin (GVD), a Salvage Regimen in Relapsed Hodgkin\u2019s Lymphoma: CALGB 59804","volume":"18","author":"Bartlett","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41409-019-0454-z","article-title":"Chemoimmunotherapy with Brentuximab Vedotin Combined with Ifosfamide, Gemcitabine, and Vinorelbine Is Highly Active in Relapsed or Refractory Classical Hodgkin Lymphoma","volume":"54","author":"Abuelgasim","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V128.22.1109.1109","article-title":"Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)","volume":"128","author":"Sureda","year":"2016","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3324\/haematol.2019.243238","article-title":"Combining Brentuximab Vedotin with Dexamethasone, High-Dose Cytarabine and Cisplatin as Salvage Treatment in Relapsed or Refractory Hodgkin Lymphoma: The Phase II HOVON\/LLPC Transplant BRaVE Study","volume":"106","author":"Kersten","year":"2021","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1200\/EDBK_238799","article-title":"Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace with Novel Agents and New Options for Salvage Therapy","volume":"39","author":"Moskowitz","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/4\/982\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:20:25Z","timestamp":1760134825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/4\/982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14040982"],"URL":"https:\/\/doi.org\/10.3390\/cancers14040982","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,15]]}}}